Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | The importance of achieving CR before stem cell transplantation in patients with AML and ALL

Francesco Lanza • 24 Oct 2022
SOHO Italy 2022
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Francesco Lanza, MD, Romagna Transplant Network, Ravenna, Italy, explains why leukemic cells should ideally be eliminated from tissues before performing stem cell transplantation in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and further highlights the importance of carefully assessing measurable residual disease (MRD) in patients. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francesco Lanza

5:25
How the AML treatment landscape is changing with the introduction of novel targeted agents
Francesco Lanza • 24 Oct 2022
2:42
Optimizing biological agents for ALL
Francesco Lanza • 17 Sep 2020
4:54
Monoclonal antibody combinations in ALL
Francesco Lanza • 17 Sep 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals